Targretin
(Bexarotene)ApprovedSmall molecule
Bexarotene is used to treat cutaneous T-cell lymphoma, a type of blood cancer that affects the skin. It works by helping to slow or stop the growth of these cancer cells.[2] Targretin is currently approved and in use across 10 indications[4].[1]
Targretin is one of 246 small molecule programs targeting Parapsoriasis. It is currently in Approved.
10
Indications
31
Total Trials
1
Active Trials
245
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Targretin
BBausch Health Americas, Inc.
Approved
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Cabenuva
GSKPreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
R-CHOP
IIncyte Biosciences Japan GK
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cutaneous T-cell lymphoma6 trials
Show 3 more trials
Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma
Completed·—·Phase 1/2·NCT00306969·18 enrolled
Non-Small Cell Lung Cancer4 trials
Show 1 more trial
Bexarotene, Tretinoin, and Combination Chemotherapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Unknown status·—·Phase 2·NCT00514293·39 enrolled
Schizophrenia3 trials
Bexarotene Treatment in Schizophrenia
Unknown status·—·Phase 3·NCT00141947·15 enrolled
Bexarotene Augmentation of Antipsychotic Treatment for Chronic Schizophrenia
Completed·—·Phase 3·NCT00535574·90 enrolled
Bexarotene and Fenretinide as Addition to Antipsychotic Treatment in Schizophrenia Patients
Withdrawn·—·Phase 3·NCT00534898
Breast Cancer3 trials
12 more indications
Acute Myeloid Leukemia2 trials
Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
Terminated·—·Phase 2·NCT00615784·24 enrolled
Study of Bexarotene in Patients With Acute Myeloid Leukemia
Completed·—·Phase 1·NCT00316030·54 enrolled
Advanced Cancers1 trial
Erlotinib (Tarceva) and Bexarotene (Targretin) Oral Capsules in Advanced Cancers of the Aerodigestive Tract
Completed·—·Phase 1·NCT01116622·24 enrolled
Lung Cancer1 trial
A Study of Paclitaxel and Carboplatin in Combination With Bexarotene Oral Capsules in Patients With Advanced Lung Cancer
Terminated·—·Phase 1/2·NCT00153842·33 enrolled
Metabolism1 trial
Thyroid Cancer1 trial
T-cell non-Hodgkin lymphoma1 trial
Chemotherapy1 trial
Myelodysplastic Syndrome1 trial
Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00425477·26 enrolled
Regulatory
FDA Approval Timeline[5]
Dec 29, 1999
TARGRETIN
NDA NDA021055
Jun 28, 2000
TARGRETIN
NDA NDA021056
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Targretin drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Bexarotene. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Retinoid X Receptor Agonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- BBausch Health Americas, Inc.